Format

Send to

Choose Destination
Curr Opin Pharmacol. 2002 Aug;2(4):374-81.

Protein tyrosine kinase inhibitors: new treatment modalities?

Author information

1
Department of Oncology, Novartis Pharma Inc., CH-4002, Basel, Switzerland. doriano.fabbro@pharm.novartis.com

Abstract

Protein tyrosine kinases (PTKs) have been recognized as attractive cell-signaling targets for drug discovery in the treatment of cancer and other diseases. Most of the PTK inhibitors are small molecules, designed to compete for, or nearby, the ATP-binding site, and are currently in phase I-III clinical trials, mainly for oncological indications. Recent efforts focused on the synthesis of selective PTK inhibitors have generated several promising clinical candidates, which recently culminated in the approval of Gleevec, the first kinase inhibitor registered for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors.

PMID:
12127869
DOI:
10.1016/s1471-4892(02)00179-0
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center